Company intelligence / Profile preview

Defensin Therapeutics ApS

Ownership: Private
Development stage: Other

Overview

Defensin Therapeutics is developing recombinant defensin-based therapies targeting immune system diseases. Its lead program, hBD‑2 for acute graft versus host disease, is in preclinical development. Other programs have targeted asthma, inflammatory bowel disease, and metabolic syndrome but remain at the preclinical stage or are inactive.[4][5] No clinical results have been published to date.

Therapeutic areas: GastroenterologyMetabolic DisordersImmunologyPulmonology
Modalities: Recombinant polypeptidesPeptides (notably defensins, such as human β-defensin 2 and α-defensins)[4][5]
Industry: Biotech

Drug pipeline

1 asset

human beta defensin 2

Preclinical

Partnerships

Dr. Falk Pharma has been involved with human β‑defensins research alongside Defensin Therapeutics ApS on some indications.[5] No major pharma partnerships disclosed.

Beyond the preview

Go deeper on Defensin Therapeutics ApS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Defensin Therapeutics ApS.